vTv Therapeutics Inc. Class A (VTVT)
NASDAQ: VTVTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
VTVT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $62.22M
- EPS (TTM)
- -$0.44
- Dividend yield
- None
- 52-week range
- 15.47 – 44.00
- Day range
- 15.47 – 16.47
- Volume / Avg
- 10.59K / 33.07K
- Beta
- —
- Shares outstanding
- 4.01M
52-week range
VTVT stock today
Shares of vTv Therapeutics (VTVT) finished lower on Nov 20 at $15.51, a drop of 5.20% or $0.85 per share, versus the S&P 500's 3.70% decline. Trading was light, with 10.59K shares changing hands, about 32% of the average daily volume. At this level, VTVT sits near the bottom of its 52-week range of $15.47 to $44.00: 64.8% below the high, set on Jan 6, 2026 and 0.3% above the low.
VTVT is down 61.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 47.5%. vTv Therapeutics has posted a net loss over the last twelve months (EPS of -$0.44), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About vTv Therapeutics
Company profilevTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Paul J. Sekhri
- Headquarters
- High Point, NC
- Employees
- 26
- IPO year
- 2015
- Website
- vtvtherapeutics.com
Financial highlights
Full financialsIn fiscal 2025, vTv Therapeutics generated $0 in revenue, down 100.0% from fiscal 2024, its first annual decline since 2023. vTv Therapeutics reported a net loss of $27.0 million, compared with a loss of $18.5 million a year earlier.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $1.02M | $0 | $2.02M | $4.00M |
| Growth | -100.00% | — | -100.00% | -49.61% | -37.56% |
| Net income | $-26.97M | $-18.46M | $-20.25M | $-19.16M | $-12.99M |
| EPS (diluted) | — | — | — | — | — |
Analyst forecast
ForecastConsensus (6 analysts)
strong_buy
Avg. price target
$56.00+261.06%
- Strong buy 0
- Buy 6
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-1.08 vs $-1.07
- Surprise
- -0.93%
VTVT news
All VTVT newsvTv Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| FBIOFortress Biotech Inc. | 1.90 | +7.34% | $64.11M | vs VTVT |
| RANIRani Therapeutics Holdings Inc. Class A | 0.5111 | -11.97% | $59.03M | vs VTVT |
| GOSSGossamer Bio Inc. | 10.72 | -4.54% | $65.57M | vs VTVT |
| PMVPPMV Pharmaceuticals Inc. | 0.876 | -33.13% | $66.17M | vs VTVT |
| PLYXPolaryx Therapeutics Inc. | 1.33 | -11.92% | $66.30M | vs VTVT |
| MNOVMedicinova Inc | 1.31 | +3.15% | $67.11M | vs VTVT |
| CINGCingulate Inc. | 4.51 | -14.26% | $67.48M | vs VTVT |
| TENXTenax Therapeutics Inc. | 1.25 | -10.07% | $56.92M | vs VTVT |
Indexes, lists and sector
vTv Therapeutics stock FAQ
What is vTv Therapeutics's stock price today?
VTVT last traded at $15.51 as of Nov 20, 4:00 PM EST, down 5.20% on the day. Prices are delayed at least 15 minutes.
Does vTv Therapeutics pay a dividend?
No. vTv Therapeutics does not currently pay a regular cash dividend.
Who is vTv Therapeutics's CEO?
Mr. Paul J. Sekhri is the chief executive officer of vTv Therapeutics Inc. Class A, which has about 26 employees.
Has VTVT ever split its stock?
Yes. The most recent VTVT stock split was a 1-for-40 split on Nov 21, 2023.
What is the VTVT 52-week high?
The 52-week high for VTVT is $44.00 and the 52-week low is $15.47. The stock is currently 64.8% below its high.